Pretreatment with the CCK-2 receptor antagonist proglumide prevented these inflammatory events in all cases. Leukocytes from rats treated with omeprazole showed increased expression of CD11b/CD18 initially in granulocytes (3 day protocol) and later in monocytes and lymphocytes (14 day protocol). These changes were not observed in animals pretreated with proglumide and were not reproduced by incubation of leukocytes from untreated animals in vitro with gastrin. Thus, hypergastrinemia induced by chronic treatment with antisecretory drugs may promote inflammation, which could partly explain their worsening effect in corpus gastritis observed in H. pylori infected patients.
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INTRODUCTION
Gastrin is a gastrointestinal hormone that plays an essential role regulating gastric acid secretion and promoting cellular growth. Its release from antral G cells is closely controlled by neuroendocrine mechanisms that are highly sensitive to local changes.
Luminal acidity exerts a negative feedback on gastrin secretion through the release of somatostatin from D cells. When acid secretion is pharmacologically inhibited, somatostatin secretion decreases and, consequently, G cells become unrestrained and provoke hypergastrinemia (Walsh, 1994) . This neuroendocrine secretory circuit is also sensitive to local inflammation. Helicobacter pylori infection and the associated gastritis reduce somatostatin and increase gastrin synthesis (Blaser and Atherton, 2004) , while G cell activity can be directly stimulated by proinflammatory cytokines (Weigert et al., 1996) . On the other hand, accumulating evidence suggests that these neuroendocrine secretions exert immunomodulatory effects themselves.
We have recently demonstrated that gastrin has a direct proinflammatory effect in rats through the activation of its CCK-2 receptors, and that hypergastrinemia induced by Helicobacter pylori components contributes to the inflammation induced by these bacterial products (Alvarez et al., 2006) . On the contrary, somatostatin displays antiinflammatory properties (Karalis et al., 1994) , and recent evidences suggest that the equilibrium between gastrin and somatostatin release is important to define the host lymphocytic response to Helicobacter infection (Takaishi et al., 2005; Zavros et al., 2003) .
Inhibition of gastric acid secretion with proton pump inhibitors (PPIs) has been proved very effective to induce healing and symptom relief in peptic ulcer and gastroesophageal reflux disease. However, many clinical studies do support an accelerating effect of PPIs on the development of atrophic gastritis in H. pyloriThis article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on as DOI: 10.1124 at ASPET Journals on October 18, 2017 jpet.aspetjournals.org Downloaded from JPET #122754 5 positive patients. This effect is usually associated to a reduction in antral gastritis and it was primarily assumed that both changes were the consequence of an alteration in the pattern of Helicobacter pylori colonization (Logan et al., 1995) . The increased corpus pH would be beneficial for bacterial survival and promote the migration of the germ from the antrum to the corpus. However, latter studies have shown aggravated corpus gastritis with no increase (Kuipers et al., 1995; Meining et al., 1997) , or even reduction Schenk et al., 2000; Moayyedi et al., 2000) , in
Helicobacter density in corpus. These evidences question the initial hypothesis and leave the mechanism responsible for the corpus deterioration unresolved.
High serum levels of gastrin before PPI therapy in H. pylori-infected patients seems to predispose to an accelerated progression in gastric atrophy during treatment (Eissele et al., 1997) , and most clinical studies showed a strong correlation between the degree of atrophic gastritis and gastrinemia (Fox and Wang, 2007) . The development of mucosal atrophy is the result of a chronic inflammatory process that finally destroys the normal gland architecture. Our hypothesis is that gastrin hypersecretion in response to treatment with antisecretory drugs may contribute to mucosal atrophy by promoting the inflammatory process. Thus, the aim of the present study is to analyze whether antisecretory drugs induce inflammation and the involvement of gastrin hypersecretion in such a response.
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METHODS
Intravital microscopy
Leukocyte-endothelial cell interactions were evaluated in fasted male SpragueDawley rats (200-250 g), the details of the experimental preparation having been described previously (Alvarez et al., 2002) . In brief, rats were anesthetized with sodium pentobarbital (65 mg/kg, i.p.). A midline abdominal incision was made and a segment of the midjejunum exteriorized and placed over a transparent pedestal for tissue transillumination. A selected loop of the exposed mesentery was continuously superfused with bicarbonate buffer saline (pH 7.4, 37 ºC, 2 ml min -1 ) and observed through an orthostatic microscope equipped with a video camera. Images were captured on videotape for playback analysis (final magnification of the video screen was x1300). and centerline red blood cell velocity were evaluated on-line and venular blood flow and venular wall shear rate (γ) were calculated as previously described (Calatayud et al., 1999) .
At the end of the experiment, the stomach of some rats was removed, fixed with paraformaldehide (4% in PBS pH 7.4) and embedded in paraffin. In some cases, a In the third protocol, animals received vehicle or omeprazole (10 or 40 mg/kg) or famotidine (30 mg/kg) daily during fourteen consecutive days and the experiment performed as before, 24 hours after the last dose.
The involvement of gastrin in the effects induced by these agents was tested by pretreating some rats with proglumide (30 mg/kg, i.p.) every time that an antisecretory drug was administered. This dose of proglumide was effective to prevent the proinflammatory effect of exogenously administered gastrin without affecting the effects induced by a common inflammatory mediator like PAF (platelet activating factor, 10 -7 M) (Alvarez et al., 2006) .
Immunohistochemical studies
Leukocyte infiltration in the gastric mucosa was analyzed by detecting the common leukocyte antigen CD45 in the leukocyte surface by inmmunohistochemistry.
Sections of the gastric corpus (5 µm) were deparaffined, hydrated and processed for antigen retrieval with alpha-chymotrypsin (Sigma Chemical CO 
Flow Cytometry Analysis
The expression of adhesion molecules was analyzed in circulating leukocytes from portal blood of animals treated during 3 or 14 days with omeprazole (40 mg/kg/day, p.o.) with or without cotreatment with proglumide. In a second set of experiments, leukocyte stimulation assays in vitro were carried out to check whether gastrin exert a direct effect on the expression of these adhesion molecules. In this case, the analysis was performed in portal whole blood from untreated animals incubated for 45 minutes at 37°C with vehicle, gastrin (10
-10 -9 M), formyl-methionyl-leucylphenylalanin (FMLP, 10 -7 M) or phorbol 12-myristate-13-acetate (PMA, 10 -7 M). The gastrin concentrations used correspond to those inducing leukocyte-endothelial cell interactions in rat mesentery (Alvarez et al., 2006) . exclude other cell types and debris. Ten thousand events were counted per sample.
All the analyses were performed with an EPICS XL-MCL Flow Cytometer (Coulter Electronics).
Materials
Omeprazole, proglumide, famotidine, FMLP and PMA were all obtained from Sigma
Chemical. Pentobarbital was from B. Braun Medical SA (Rubi, Barcelona, Spain).
The antibodies were from Serotec (Oxford, UK), Abcam (Cambridge, UK) or Dako Cytomation (Glostrup, Denmark). Gastrin RIA kit was purchased from IBL Hamburg, Germany.
Statistical Analysis
All values are mean ± sem. Data within groups were compared using the Student's ttest or a one-way ANOVA followed by a Newman-Keuls post hoc test. The differences were considered significant when the P value was < 0.05. fold increase with respect to the control level 5 hours after dosing. In the same circumstances, famotidine (30 mg/kg) increased gastrin levels 2.5 times (Table 1) .
Rats receiving omeprazole (40 mg/kg/day) during three consecutive days showed normal gastrinemia 24 h after the last dose when the intravital experiment was performed (Table 1) . However, the animals following this three-day regime presented hypergastrinemia for the most part of the day previous to the experiment since gastrin levels 8 hours after the third dose of omeprazole were higher than those observed 5 hours after a single dose and remained elevated twelve hours after dosing ( Figure 3 ).
When the antisecretory treatment was extended to 14 days, both omeprazole (40 mg/kg/day) and famotidine (40 mg/kg/day) induced a significant increase in the gastrin levels detected 24 hours after the last dose, although the effect was higher with the PPI (Table 1) (Table 2) .
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Conversely, monocytes and lymphocytes in these blood samples showed reduced Lselectin and increased CD11b/CD18 in the cellular surface. These changes were not observed in animals cotreated with proglumide and omeprazole ( Figure 6 ). As occurred in the three-day protocol, the expression of CD11a, CD11c, CD18 or CD49
was not affected by any treatment (Table 3 ).
In vitro treatment with different concentrations of gastrin capable of inducing leukocyte-endothelial cell interactions in vivo (Alvarez et al., 2006) , did not modify the expression of the integrin CD11b/CD18 in either granulocytes, monocytes or lymphocytes ( Figure 7 ).
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DISCUSSION
The present study demonstrates that treatment with antisecretory drugs induce inflammatory events in the rat mesentery through the release of gastrin and the consequent activation of CCK-2 receptors.
We have analyzed the acute effects on leukocyte-endothelium interactions of two treatments inducing a maximal inhibition of acid secretion through different mechanisms, proton pump blocking with omeprazole (40 mg/kg) or H2-receptor antagonism with famotidine (30 mg/kg) (Decktor et al., 1989) , and the effects were very similar: increased number of rolling and adherent leukocytes, with little effect on leukocyte emigration. When we analyzed the influence of chronic antisecretory treatments, augmented rolling and adhesion, and a slight non-significant increase in emigration were observed in animals receiving this dose of omeprazole during three days or rats treated during fourteen days with famotidine or a lower dose of omeprazole (10 mg/kg). However, a complete inflammatory response, with increased rolling, adhesion and significant emigration was observed in rats receiving the full inhibitory dose of omeprazole for fourteen days. Moreover, we observed that this chronic treatment with the PPI induced gastritis since augmented leukocyte infiltration was observed in the gastric corpus of these animals.
We recently shown that exogenous gastrin exerts a proinflammatory action through CCK-2 receptors. These receptors were detected in mesenteric macrophages and PMNs, and two different antagonists (proglumide and L-365,260) completely prevented gastrin effects (Alvarez et al., 2006) . In the present study, pretreatment with proglumide prevented the inflammatory events in every protocol used, indicating that they are mediated by gastrin. In fact, we observed a relationship between the This article has not been copyedited and formatted. The final version may differ from this version. Leukocytes from animals co-treated with omeprazole and proglumide did not show any alteration in the expression of these adhesion molecules, which points to gastrin as the ethyologic factor for these differences. However, the sequential changes in the cell type affected argue against a direct molecular effect of gastrin. They rather seem to be part of the complete response occurring in vivo, a view reinforced by the unaltered expression of these molecules on leukocytes treated ex vivo with gastrin.
These data indicate that gastrin must be activating its receptor in some structure only present in vivo. Gastrin stimulates gastric enterochromaffin-like cells to release histamine (Walsh, 1994) , which is a common mediator of acute inflammatory reactions. The ability of histamine to induce leukocyte recruitment was initially attributed to H 1 receptor activation (Asako et al., 1994) , but later studies have shown that the other receptor types (H 2-4 ) may also modulate the immune function (Akdis and Simons, 2006) . We observed that the proinflammatory effect induced by gastrin superfusion in the mesentery occurs without degranulation of mastocytes, the main source of histamine in this tissue, and after H 1 receptor blockade (Alvarez et al., This article has not been copyedited and formatted. The final version may differ from this version. 2006). Both results suggest that the observed effects are at least partially independent of endogenous histamine. However, we cannot discard that histamine released in the gastric mucosa in response to gastrin could still induce some inflammatory events through the H 3-4 receptors (Akdis and Simons, 2006; Zhang et al., 2007) . On the other hand, our previous results point to macrophages as one likely target for gastrin. The activation of these resident cells would trigger the initial signal for leukocytes to interact with the venular endothelium and start the inflammatory process. Once initiated, and provided that the original stimulus continues, the inflammation would take off and follow its own kinetics. Gastrin may also act on endothelial cells where it seems to modify the expression of adhesion molecules and increase chemokine secretion (Lefranc et al., 2004; Clarke et al., 2006) . We also detected CCK-B receptors in mesenteric PMNs, whereas others reported its presence in mononuclear cells (Sacerdote et al., 1991; Schmitz et al., 2001 ).
Although gastrin did not affect the expression of adhesion molecules in leukocytes in our in vitro experiments, it is possible that plasma gastrin could modify their behavior once they are activated by the ongoing inflammatory process.
Previous reports describing the modulation by gastrin of leukocyte function showed a parallelism between the effects observed in human and rat cells (Sacerdote et al., 1988) . Thus, our results could explain why chronic treatment with antisecretory drugs induce an aggravating effect on H. pylori induced gastritis in humans (Fox and Wang, 2007) and animals (Takaishi et al., 2005) . This deleterious effect has been mainly observed with PPIs, because they are the principal drugs used chronically to treat GERD. The few studies analyzing the effects of anti-H2 agents showed analogous changes albeit of lower intensity (Meining et al., 1997; Meining et al., 1998) . This indicates that this adverse event is not related with the mechanism of action of these drugs but with their common hyposecretory effects, and the same is true for the hypergastrinemic response. Furthermore, PPIs seem to be more powerful than anti-H2 agents in all of these actions, in patients and in the present study, which further supports the link between these three effects.
Recent studies indicate that PPIs may reduce leukocyte-endothelial cell interactions in vitro (Yoshida et al., 2000; Handa et al., 2006) , an effect observed with drug concentrations probably reached, at least transiently, in our rats (Lee et al., 2007) .
However, our results suggest that, if these anti-inflammatory actions are taking place in vivo, they are clearly overwhelmed by the pro-inflammatory effect derived from hypergastrinemia.
The presently reported inflammatory events contrast with the significant efficacy of antisecretory drugs to reduce GERD symptoms and cure peptic ulcers in humans.
Their therapeutic value resides in their high efficiency increasing luminal pH, as was summarized in the old axiom of "no acid, no ulcer". This potent effect could conceal the proinflammatory actions, which could possibly arise under the influence of an acid-independent inflammatory stimulus such as H. pylori. However, we observed that omeprazole treatment induces gastritis in rats without H. pylori infection. This difference could be due to the high doses used in the present study to accelerate the changes induced more gradually in humans. Alternatively, rodents could be more sensitive than humans to the proinflammatory effect of gastrin as occurs with its growth promoting action (Watson et al., 2006) . Finally, the proinflammatory effect of gastrin may be facilitated by the overgrowing of other microorganisms in response to the increased pH (Zavros et al., 2002) . To conclude, this study confirms the proinflammatory activity of gastrin and adds to the growing evidence indicating that this hormone has varied molecular and functional consequences beyond stimulation of gastric acid secretion or cellular growth promotion (Dockray et al., 2005) . Further research is required in order to define the relevance of this effect of gastrin in patients suffering hypergastrinemia as a consequence of H. pylori infection, antisecretory treatments or both.
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